A study of therapeutic effect of blood ozone therapy of severe Covid-19 patients

Study of intra-venous ozonated auto-hemotherapy on severe cases of COVID-19: A randomized clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200616047792N1

Enrollment

Registered

2020-08-03

Start date

2020-08-18

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. virus identified, Clinically-epidemiologically diagnosed COVID-19

Interventions

Intervention 1: Control group: This group will receive the Iranian nationally implemented treatment protocol of Covid-19, which include any of the following, Hydroxychloroquine 200mg po BD or Chlroqui

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Severe cases of Covid-19 with chest CT changes in the form of peripheral uni- or bilateral ground glass opacity(s) in combination with any of the below: RR greater than 24, O2 Sat less than 93%, BP less than 90/60, decreased level of consciousness.

Exclusion criteria

Exclusion criteria: G6PD Deficiency Coagulopathies and thrombocytopenia Hx of seizure Hypothyroidism Pancreatitis Hemophilias Acute alcohol poisoning Pregnancy and breast feeding Allergy to ozone and ozonated products

Design outcomes

Primary

Measure	Time frame
Length of hospital stay. Timepoint: Daily since the time of hospitalization. Method of measurement: patient's file.	—

Secondary

Measure	Time frame
Need for ICU. Timepoint: Daily since hospitalization. Method of measurement: Patient's file.;Duration of ICU stay. Timepoint: Daily since ICU stay. Method of measurement: Patient's file.;Need for mechanical ventilation. Timepoint: Daily since hospitalization. Method of measurement: Patient's file.;Duration of need for mechanical ventilation. Timepoint: Daily since mechanical ventilation. Method of measurement: Patient's file.;Case fatality rate. Timepoint: Daily since intervention. Method of measurement: Patient's file.;C-reactive protein. Timepoint: Thrice weekly. Method of measurement: Biochemistry method.;White blood cell count. Timepoint: Thrice weekly. Method of measurement: Cell counter.;Change in lung CT scan appearance. Timepoint: End of week one and week two. Method of measurement: Chest spiral CT scan.;ESR. Timepoint: Thrice weekly. Method of measurement: Biochemistry method.	—

Measure

Time frame

Need for ICU. Timepoint: Daily since hospitalization. Method of measurement: Patient's file.;Duration of ICU stay. Timepoint: Daily since ICU stay. Method of measurement: Patient's file.;Need for mechanical ventilation. Timepoint: Daily since hospitalization. Method of measurement: Patient's file.;Duration of need for mechanical ventilation. Timepoint: Daily since mechanical ventilation. Method of measurement: Patient's file.;Case fatality rate. Timepoint: Daily since intervention. Method of measurement: Patient's file.;C-reactive protein. Timepoint: Thrice weekly. Method of measurement: Biochemistry method.;White blood cell count. Timepoint: Thrice weekly. Method of measurement: Cell counter.;Change in lung CT scan appearance. Timepoint: End of week one and week two. Method of measurement: Chest spiral CT scan.;ESR. Timepoint: Thrice weekly. Method of measurement: Biochemistry method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnam Sheibani

Ahvaz University of Medical Sciences

behnamshei@gmail.com+98 61 3392 5312

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026